Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dutasteride/tadalafil - Dongkook Pharmaceutical

Drug Profile

Dutasteride/tadalafil - Dongkook Pharmaceutical

Alternative Names: DKF 313; Tadalafil/dutasteride - Dongkook Pharmaceutical

Latest Information Update: 06 Oct 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Dongkook Pharmaceutical
  • Class Antiandrogens; Antihypertensives; Antineoplastics; Aza compounds; Azasteroids; Benzodioxoles; Carbolines; Erectile dysfunction therapies; Eye disorder therapies; Fluorinated hydrocarbons; Gastrokinetics; Heart failure therapies; Indenes; Indoles; Ischaemic heart disorder therapies; Ketones; Pyridones; Quinolines; Skin disorder therapies; Small molecules; Vascular disorder therapies; Vasodilators
  • Mechanism of Action Cholestenone 5-alpha reductase inhibitors; Testosterone antagonists; Type 5 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Benign prostatic hyperplasia

Most Recent Events

  • 12 Jun 2023 Dongkook Pharmaceutical completes a phase III trial in Benign prostatic hyperplasia in South Korea (PO) (NCT04947631)
  • 27 Jul 2021 Phase-III clinical trials in Benign prostatic hyperplasia in South Korea (PO) (NCT04947631)
  • 01 Jul 2021 Dongkook plans a phase III trial for Benign prostatic hyperplasia in South Korea in July 2021 (NCT04947631)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top